Featured Funding Opportunities
Funding Opportunites now available for the Undiagnosed Diseases Network
The NIH is now inviting applications for Phase II of the UDN via the following five Funding Opportunities:
A Coordinating Center for the UDN to serve as a resource to assist in infrastructure support and maintenance, internal and external UDN communications, facilitating collaboration, data sharing, and protocol development.
Eight to Ten Clinical Sites for participants seen through the UDN. Each clinical site will be expected to be able to recruit, select, evaluate, and follow participants with disorders in any clinical specialty, adult and pediatric, and maintain clinical evaluations at a rate of 30 affected UDN participants per year.
Metabolomics Cores for participants seen through the UDN. The Metabolomics Core(s) will be expected to provide expertise in at least two of three key areas: glycans, lipids, and mitochondria.
One to two Sequencing Cores to provide CAP-accredited and/or CLIA-certified sequencing for participants seen through the UDN.
- Model Organisms Screening Center for the Undiagnosed Diseases Network (UDN) Phase II (U54) (RFA-RM-17-017)
One to two Model Organism Screening Centers to evaluate the putative pathogenicity and function of gene variants identified through the UDN. The Model Organism Screening Center(s) will be expected to evaluate and select the most informative variants and conduct research using Drosophila and zebrafish at minimum to assist in the diagnosis of UDN participants.
Letters of intent are due by October 2, 2017 and final applications are due by November 2, 2017.
New Funding Opportunities from the Metabolomics Program
The NIH Common Fund Metabolomics Program recently issued four new Funding Opportunity Announcements (FOAs) for the program’s second stage of funding. These funding opportunities will focus on the following topics:
- The continued development of a robust National Metabolomics Data Repository to store, and make publicly available, raw and processed metabolomic data. (RFA-RM-17-011)
- The development of novel tools to facilitate metabolomics data analysis and interpretation. (RFA-RM-07-012)
- The establishment of Compound Identification Development Cores to develop innovative approaches to enhance compound identification of the most significant, biomedically-relevant unknown metabolites. (RFA-RM-17-013)
- The establishment of a Stakeholder Engagement and Program Coordination Center to coordinate the required activities of the Common Fund Metabolomics Consortium and engage invested communities in developing and disseminating consensus best practices in metabolomics. (RFA-RM-17-014)
Letters of intent are due by September 12, 2017 and final applications are due by October 20, 2017.
This page last reviewed on August 25, 2017